Skip to main content

Day: November 19, 2019

Alternus Energy Reports Third Quarter 2019 Results and Files its First Quarterly Report with the Securities and Exchange Commission

Q3 Revenue Increased 22% Year-Over-YearGross Margin Improved to 75.3% Due to Better Revenue MixNEW YORK, Nov. 19, 2019 (GLOBE NEWSWIRE) — Alternus Energy Inc. (OTC: ALTN), a global renewable energy company, today announced its financial results for the third quarter ended September 30, 2019.Key Financial Highlights for Q3 2019:Revenues increased by 22% to $0.993 millionGross profit increased by 71% to $0.748 millionGross margin improved to 75%, up from 54%Adjusted EBITDA (a non-GAAP measurement) declined to a loss of $0.132 million from a positive $0.212 million in 2018Key Business Highlights for Q3 2019:Filed a SEC Form 10 on August 13 to become a SEC reporting companyFiled first SEC Form 10-Q with SEC for three and nine months ended September 30, 2019“We are very pleased with our strong third quarter results year-over-year, led...

Continue reading

Independent Bank Corporation Announces Date for Its Fourth Quarter 2019 Earnings Release

GRAND RAPIDS, Mich., Nov. 19, 2019 (GLOBE NEWSWIRE) — Independent Bank Corporation (NASDAQ: IBCP), the holding company of Independent Bank, a Michigan-based community bank, announced that it expects to issue its 2019 fourth quarter and full year financial results on Thursday, Jan. 23, 2020, at approximately 8:00 am ET. The release will be available on the Internet at IndependentBank.com within the “News” section of the “Investor Relations” area of the Company’s website.Brad Kessel, President and CEO, Rob Shuster, retiring CFO, and Steve Erickson, incoming CFO will review the quarterly and full year results in a conference call for investors and analysts beginning at 11:00 am ET on Thursday, Jan. 23, 2020.To participate in the live conference call, please dial 1-866-200-8394. Also the conference call will be accessible through an...

Continue reading

Scatec Solar and FMO enter equity partnership for the Chigirin project in Ukraine

Oslo, 19 November 2019: Scatec Solar has signed an agreement with FMO, the Dutch development bank, for FMO to take a 40% equity stake in Scatec Solar’s 55 MW Chigirin project in Ukraine. The total investment for the project is estimated at EUR 54 million and is funded by non-recourse debt financing from the European Bank for Reconstruction and Development (EBRD), The Nordic Environment Finance Corporation (NEFCO) and Swedfund. FMO’s equity stake is financed by the Access to Energy Fund, which FMO manages on behalf of the Dutch government.“We are pleased to announce this second equity co-investment with our long-term partner FMO. We are working with FMO as a debt and equity partner on a range of projects in Ukraine and internationally and we expect more cooperation in the years to come”, says Raymond Carlsen CEO of Scatec Solar.“After...

Continue reading

ArcelorMittal announces the issuance of €750,000,000 1.000 per cent.  notes due 19 May 2023 and €750,000,000 1.750 per cent. notes due 19 November 2025 under its €10,000,000,000 EMTN Programme

 19 November 2019 – 17:15 CETArcelorMittal announces the issuance of €750,000,000 1.000 per cent. notes due 19 May 2023 (the “2023 Notes”) and €750,000,000 1.750 per cent. notes due 19 November 2025 (the “2025 Notes” and together with the 2023 Notes, the “Notes”).The issuance closed today. The Notes were issued under ArcelorMittal’s €10,000,000,000 wholesale Euro Medium Term Notes Programme.The proceeds of the issuance will be used for general corporate purposes including refinancing of existing indebtedness.Important note: This press release does not, and shall not, in any circumstances constitute a public offering by ArcelorMittal of the Notes nor an invitation to the public in connection with any offer. No communication and no information in respect of the issuance of the Notes may be distributed to the public in any jurisdiction where...

Continue reading

Genmab Announces European Marketing Authorization for DARZALEX® (Daratumumab) in Combination with Lenalidomide and Dexamethasone in Frontline Multiple Myeloma

Company AnnouncementDARZALEX® approved in Europe in combination with lenalidomide and dexamethasone as treatment for adult patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplantApproval follows positive opinion by European Committee for Medicinal Products for Human Use (CHMP) in OctoberApproval based on data from Phase III MAIA studyCopenhagen, Denmark; November 19, 2019 – Genmab A/S (Nasdaq: GMAB) announced today that the European Commission (EC) has granted marketing authorization for DARZALEX® (daratumumab) in combination with lenalidomide and dexamethasone (Rd) as treatment for adult patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant (ASCT). The EC approval follows a positive opinion issued for DARZALEX by the CHMP of the European Medicines...

Continue reading

Laguna Treatment Hospital Welcomes New Alumni Services Manager

ALISO VIEJO, Calif., Nov. 19, 2019 (GLOBE NEWSWIRE) — Laguna Treatment Hospital, an American Addiction Centers facility and leading provider of substance use treatment, has welcomed Laura Giffin as the facility’s Alumni Services Manager. In her new role, Giffin plans to further incorporate Laguna Treatment Hospital into the community she calls home.Addiction is an illness very personal to Giffin. Growing up, she witnessed the actions, consequences and untimely deaths of loved ones due to the disease. After her first drink at age 12, she learned that addiction also affected her. After a number of years of not addressing her issues with alcohol, a tumultuous relationship and a brief relapse, Giffin ultimately sought and maintained her sobriety for her two sons.Almost immediately after beginning life in recovery, she battled a number...

Continue reading

Tauriga Sciences, Inc. Finalizes its Alternative Tauri-Gum Package Designs and Focuses on Large National Retail Chains

New York, NY, Nov. 19, 2019 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE — Tauriga Sciences, Inc. (OTCQB: TAUG) (“Tauriga” or the “Company”), a revenue generating Company that operates through the development, distribution, and licensing of proprietary products as well as the evaluation of potential acquisition opportunities and equity investments, today announced that is has finalized its alternative Tauri-Gum™ package designs and continues to focus efforts on securing potential orders from large national retail chains (“national retailers”).  The Company has established an alternative package design for its 3 blister pack flavors (Mint, Blood Orange and Pomegranate), which essentially removes the decorative cannabis leaves – while substituting images of each respective fruit/plant.  The Company believes that the availability of these...

Continue reading

IGE+XAO: Statement regarding the total number of shares and voting rights composing the registered capital on 31 October 2019

IGE+XAOSociété Anonyme with capital of 5,021,866.85 eurosHead office : 16 Boulevard Déodat de Séverac31770 COLOMIERS338 514 987 RCS ToulouseSIRET: 338 514 987 000 76 – VAT number: FR 783.385.149.87Regulated informationStatement regarding the total number of shares and voting rights composing the registered capital on 31 October 2019In accordance with the article L.233-8 II of the French Commercial Code and with the article 223-16 of the French Financial Market Authority (AMF) General Rule.Toulouse, 19 November 2019Total number of shares composing the registered capital: 1,304,381Total number of voting rights:Gross (1): 1,334,404Net (2): 1,332,038(1) In conformity with the article 223-11 of the AMF General Rule, the total number of voting rights is calculated on the basis of the whole shares composing the registered capital.(2) The net...

Continue reading

IGE+XAO : Déclaration du nombre total d’actions et de droits de vote composant le capital social au 31 octobre 2019

IGE+XAOSociété Anonyme au capital de 5 021 866,85 eurosSiège social : 16 Boulevard Déodat de Séverac31770 COLOMIERS338 514 987 RCS ToulouseSIRET : 338 514 987 000 76 – N° TVA intracommunautaire : FR 783.385.149.87Information réglementéeDéclaration du nombre total d’actions et de droits de vote composant le capital social au 31 octobre 2019Conformément à l’article L.233-8 II du Code de Commerce et à l’article 223-16 du Règlement général de l’Autorité des Marchés Financiers Toulouse, le 19 novembre 2019Nombre total d’actions composant le capital social : 1 304 381Nombre total de droits de vote :Brut (1) : 1 334 404NET (2) : 1 332 038(1) Conformément à l’article 223-11 du Règlement général de l’AMF, le nombre total de droits de vote est calculé sur la base de l’ensemble des actions composant le capital social.(2) Le nombre total net...

Continue reading

12 ReTech Corporation Releases its 3rd Quarter FY2019 Financial Results and Discusses the Significance of its Recent Bluwire Acquisition.

3rd Quarter 2019 Revenues Were Up 345% Over the Same Period in 2018.Adjusted Net Profits Were Generated for the First Time in the Company’s History.Las Vegas, NV & Hong Kong, Nov. 19, 2019 (GLOBE NEWSWIRE) — 12 ReTech Corporation (OTC: RETC), released its 3rd Quarter, 2019 financial results yesterday and showed further progress in improving the operations of their business with increased revenues and decreased operational expenses which resulted in reduced operational losses.The Company has improved its year over year operational results by integrating its three USA acquired consumer micro-brands so that they can work together as a cohesive business unit. This effort has resulted in reduced overhead expenses. With the newly acquired Bluwire Group retail stores, the Company plans to take advantage of additional synergies. Also,...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.